Taranjit S Gujral
Overview
Explore the profile of Taranjit S Gujral including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
54
Citations
1059
Followers
0
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
21.
Kang Y, Vijay S, Gujral T
iScience
. 2022 May;
25(5):104228.
PMID: 35494249
Immunotherapy has shown significant promise as a treatment for cancer, such as lung cancer and melanoma. However, only 10%-30% of the patients respond to treatment with immune checkpoint blockers (ICBs),...
22.
Xue C, Corey E, Gujral T
Cancers (Basel)
. 2022 Apr;
14(7).
PMID: 35406510
Metastatic prostate cancer (PC) is the second leading cause of cancer deaths in males and has limited therapeutic options. The lack of preclinical models for advanced stage PC represents one...
23.
Nishida-Aoki N, Gujral T
Cancer Res
. 2021 Dec;
82(3):433-446.
PMID: 34903600
Tumor-associated macrophages (TAM) are an important component of the tumor microenvironment (TME) that can promote tumor progression, metastasis, and resistance to therapies. Although TAMs represent a promising target for therapeutic...
24.
Arakaki A, Szulzewsky F, Gilbert M, Gujral T, Holland E
Neuro Oncol
. 2021 Nov;
23(23 Suppl 5):S4-S15.
PMID: 34725698
Patients with rare central nervous system (CNS) tumors typically have a poor prognosis and limited therapeutic options. Historically, these cancers have been difficult to study due to small number of...
25.
Bello T, Paindelli C, Diaz-Gomez L, Melchiorri A, Mikos A, Nelson P, et al.
Proc Natl Acad Sci U S A
. 2021 Oct;
118(40).
PMID: 34593636
Castration-resistant prostate cancer (CRPC) is an advanced subtype of prostate cancer with limited therapeutic options. Here, we applied a systems-based modeling approach called kinome regularization (KiR) to identify multitargeted kinase...
26.
Chan M, Vijay S, McNevin J, McElrath M, Holland E, Gujral T
Mol Syst Biol
. 2021 Sep;
17(9):e10426.
PMID: 34486798
Although 15-20% of COVID-19 patients experience hyper-inflammation induced by massive cytokine production, cellular triggers of this process and strategies to target them remain poorly understood. Here, we show that the...
27.
Bello T, Chan M, Golkowski M, Xue A, Khasnavis N, Ceribelli M, et al.
Cell Rep Methods
. 2021 Jul;
1(2).
PMID: 34296206
The ever-increasing size and scale of biological information have popularized network-based approaches as a means to interpret these data. We develop a network propagation method that integrates kinase-inhibitor-focused functional screens...
28.
Arakaki A, Pan W, Wedegaertner H, Roca-Mercado I, Chinn L, Gujral T, et al.
J Cell Sci
. 2021 Mar;
134(8).
PMID: 33722977
The α-arrestin domain containing protein 3 (ARRDC3) is a tumor suppressor in triple-negative breast carcinoma (TNBC), a highly metastatic subtype of breast cancer that lacks targeted therapies. Thus, understanding the...
29.
Horowitz L, Rodriguez A, Au-Yeung A, Bishop K, Barner L, Mishra G, et al.
Lab Chip
. 2020 Nov;
21(1):122-142.
PMID: 33174580
As preclinical animal tests often do not accurately predict drug effects later observed in humans, most drugs under development fail to reach the market. Thus there is a critical need...
30.
Golkowski M, Lau H, Chan M, Kenerson H, Vidadala V, Shoemaker A, et al.
Cell Syst
. 2020 Aug;
11(2):196-207.e7.
PMID: 32755597
Hepatocellular carcinoma (HCC) is a complex and deadly disease lacking druggable genetic mutations. The limited efficacy of systemic treatments for advanced HCC implies that predictive biomarkers and drug targets are...